# Myriad Genetics (MYGN) — Earnings

MYGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mygn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.25 |
| EPS estimate | −$0.06 |
| EPS surprise | −331.78% |
| Revenue surprise | −7.44% |
| Revenue | $190.7M |
| Revenue estimate | $206.0M |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/899923/000089992326000072/mygn-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/b191991e-4d26-cde7-8aa6-baa94296d50f.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | −$0.06 | −$0.25 | -331.78% | $206.0M | $190.7M |
| Q1 2026 | May 5, 2026 | −$0.07 | −$0.09 | -32.35% | $202.4M | $200.4M |
| Q4 2025 | Feb 23, 2026 | −$0.01 | $0.04 | 368.46% | $207.4M | $209.8M |
| Q3 2025 | Nov 3, 2025 | −$0.01 | $0.00 | 100.00% | $204.8M | $205.7M |
| Q2 2025 | Aug 5, 2025 | −$0.01 | $0.05 | 741.03% | $201.9M | $213.1M |
| Q1 2025 | May 6, 2025 | −$0.05 | −$0.03 | 44.95% | $200.5M | $195.9M |
| Q4 2024 | Feb 24, 2025 | $0.03 | $0.03 | -1.32% | $211.6M | $210.6M |
| Q3 2024 | Nov 7, 2024 | $0.02 | $0.06 | 220.86% | $210.8M | $213.3M |
| Q2 2024 | Aug 6, 2024 | −$0.01 | $0.05 | 527.35% | $206.4M | $211.5M |
| Q1 2024 | May 7, 2024 | −$0.10 | −$0.01 | 90.40% | $193.5M | $202.2M |
| Q4 2023 | Feb 27, 2024 | $0.01 | $0.04 | 181.69% | $194.8M | $196.6M |
| Q3 2023 | Nov 6, 2023 | −$0.08 | −$0.03 | 60.32% | $182.3M | $191.9M |
| Q2 2023 | Aug 3, 2023 | −$0.08 | −$0.08 | 1.36% | $187.2M | $183.5M |
| Q1 2023 | May 3, 2023 | −$0.19 | −$0.21 | -8.64% | $171.5M | $181.2M |
| Q4 2022 | Feb 28, 2023 | −$0.16 | −$0.12 | 26.52% | $169.5M | $177.8M |
| Q3 2022 | Nov 1, 2022 | −$0.04 | −$0.19 | -375.00% | $170.1M | $156.4M |
| Q2 2022 | Aug 4, 2022 | $0.03 | $0.04 | 60.00% | $171.0M | $179.3M |
| Q1 2022 | May 5, 2022 | −$0.08 | −$0.03 | 63.86% | $156.7M | $164.9M |
| Q4 2021 | Feb 24, 2022 | −$0.02 | −$0.02 | 15.61% | $163.0M | $160.8M |
| Q3 2021 | Nov 2, 2021 | −$0.02 | −$0.02 | -12.36% | $165.0M | $167.3M |

## Frequently Asked Questions

### When did Myriad Genetics (MYGN) last report earnings?

Myriad Genetics last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did MYGN beat earnings estimates?

No. Myriad Genetics reported EPS of −$0.25 for Q2 2026 against a −$0.06 estimate — a 331.78% miss.

### How much revenue did MYGN report last quarter?

Myriad Genetics reported $190.7M in revenue for Q2 2026, against a consensus estimate of $206.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).